Androgen Receptor Signaling May Contribute to Targeted Therapy Resistance in Patients With Melanoma

Source: The Asco Post, June 2022

Androgen receptor (AR) signaling may affect response to BRAF/MEK inhibitor therapy in both male and female patients with melanoma, according to findings from a study published by Vellano et al in Nature. The report provides a new target to combat therapeutic resistance and one possible answer to why men face a poorer prognosis than women when diagnosed with melanoma.

The AR is a type of nuclear receptor that is activated by the male sex hormone testosterone. Females have lower levels of androgens, including testosterone. This research confirms the impact of sex on response to BRAF/MEK targeted therapy, and shows—for the first time—that these inhibitors increase AR signaling, leading to therapeutic resistance and poor response to treatment. In preclinical models of melanoma, blocking the AR improved response to BRAF/MEK targeted therapy in both males and females.

“This study, coupled with other recent publications looking at the impact of AR signaling on response to other types of cancer therapies, such as immune checkpoint blockade, has enormous implications for the field,” said senior corresponding author Jennifer Wargo, MD, Professor of Genomic Medicine and Surgical Oncology at The University of Texas MD Anderson Cancer Center. “We know males and females get cancer at different rates and have different mortality. Our research raises the possibility that the AR and testosterone may be at play and offers a new target to improve response to treatment in both sexes.”